The Largest Deals, Fundraising and Exits of 2016 in European Biotech
Curious about which technologies have attracted the most cash in biotech finance this year? Here's a…
Curious about which technologies have attracted the most cash in biotech finance this year? Here's a…
Although 2016 has brought plenty of good news in medical advances, biotech is an industry…
Today marks an inflection point in the future of medicine: both parties fighting for the…
CRISPR is going to change a lot in the life science industry and is perceived…
Troubled waters in the CRISPR field: CRISPR Therapeutics' IPO hits an unexpectedly low price. It…
Bayer and CRISPR Therapeutics have invested $373M in a joint venture, Casebia, as the latest…
Everyone wants to invest in CRISPR Therapeutics, it seems. The Basel and Cambridge, US biotech…
CRISPR Therapeutics has struck a deal with Anagenesis Biotechnologies, which has key technology for muscle…
CRIPSR's hype is not going down yet. CRIPSR/Cas9 or Cpf1 is a revolutionising gene editing…
CRISPR is already revolutionizing Biotechnology. However, like every biotech revolution, there then follows a patent…
A new strategic movement in the hot CRISPR field: CRISPR Therapeutics ramps up its leadership…
As the CRISPR-Cas9 war still goes on, CRISPR Therapeutics closed a Series A and B…